Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EMEND

« Back to Dashboard
Emend is a drug marketed by Merck and Merck And Co Inc and is included in two NDAs. It is available from three suppliers. There are five patents protecting this drug and three Paragraph IV challenges.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

Summary for Tradename: EMEND

Suppliers: see list3

Clinical Trials for: EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010RXYes5,691,336<disabled>YY<disabled>
CAPSULE;ORAL021549-003Jun 30, 2006RXNo5,719,147<disabled>YY<disabled>
CAPSULE;ORAL021549-002Mar 26, 2003RXYes6,096,742<disabled>YY<disabled>
Merck And Co Inc
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNNo5,716,942<disabled><disabled>
CAPSULE;ORAL021549-001Mar 26, 2003RXNo6,096,742<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EMEND

Drugname Dosage Strength RLD Submissiondate
fosaprepitant dimeglumineInjection115 mg/vialEmend1/25/2012
fosaprepitant dimeglumineInjection150 mg/vialEmend1/25/2012
aprepitantCapsule40 mg, 80 mg and 125 mgEmend11/3/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn